These supplements are designed to stimulate the body’s production of human growth hormone (HGH). This boosted production can result in various benefits, including increased muscle growth ...
New-York based Remedy will continue to contribute to cost of developing the drug, but Biogen will take over its clinical trial programme. The deal centres on a $120 million upfront payment ...
Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the industry. Please send the good word—or the bad—from your shop to Darren ...
Healthcare analytics company PurpleLab joined the Network Advertising Initiative. Biogen and Neomorph announced a multi-target research collaboration to discover and develop molecular glue degraders ...
Biogen Inc. (NASDAQ:BIIB) the central nervous system disease drug developer based in Cambridge Massachusetts, reported its Q3 earnings yesterday, Wednesday, October 30. First, let's look at some ...
Two days after Monte Rosa Therapeutics Inc. signed a molecular glue degrader deal with Novartis AG, two other companies, Biogen Inc. and Neomorph Inc., are moving forward in the same space in a ...
Biogen’s investors are growing restless. Wednesday’s third-quarter earnings call checked most of the boxes for a successful report. The company raised its full-year ...
Oct 30 (Reuters) - Biogen (BIIB.O), opens new tab raised its annual profit forecast on Wednesday, as new treatments and cost-cutting measures offset declining sales of its multiple sclerosis drugs.
Despite a somewhat ambling launch, Biogen’s Eisai-partnered Alzheimer’s disease drug Leqembi continues to grow. But to truly unlock the amyloid-busting antibody’s potential, the company will ...
(Reuters) - Biogen (NASDAQ:BIIB) raised its annual profit forecast on Wednesday, as new treatments and cost-cutting measures offset declining sales of its multiple sclerosis drugs. However ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback